LETMD1

Adene Sanchez/Getty Images It’s not the COVID-19 vaccine that will get you, say reproduction experts. It’s the virus, SARS-CoV-2, that may cause infertility. “There is evidence to suggest that infection with SARS-CoV-2 has the potential to impact both male fertility, female fertility, and certainly the health of a pregnancy of someone infected,” Dr. Jennifer Kawwass, a reproductive endocrinologist and associate professor at the Emory University School of Medicine in Atlanta told NBC News. “And there is simultaneously no evidence that the vaccine has any negative impact on male or female fertility.” Despite this striking lack of scientific evidence and the official recommendation of the Center for Disease Control and Prevention (CDC) that “all pregnant people or people who are thinking about becoming pregnant” get vaccinated, the myth persists and is a concern listed by the vaccine-hesitant. The real cause for concern is the virus, Kawwass explained, and it lies in the fact that both male and female reproductive organs contain cell receptors the virus targets. These include ACE-2, TMPRSS2, and CD147, all found in the cells of the testes, epididymis, prostate, seminal vesicles and ovarian follicles, and all known to be major SARS-CoV-2 entry factors. While the SARS-CoV-2 virus, and the disease it causes, continue to be an enigma, there is precedent for viral infections—such as the human papillomavirus (HPV), hepatitis B, hepatitis C, and HIV—being linked to infertility. SARS-CoV-2, of course, is a respiratory virus, but real-world evidence has demonstrated that its effects are not limited to the respiratory system. Recognized symptoms of long COVID—running rampant in the recovered—include fatigue, cognitive problems, shortness of breath, or racing heartbeat. Also, the high fever of 102 degrees Fahrenheit for at least three days associated with active COVID-19 has been said to cause infertility, particularly in men. “We know quite a lot about viruses, flus, and male infertility,” said reproductive urologist Dr. Paul Turek. “Seasonal flus are known to reduce male fertility … We think that it’s due to the fever associated with the illness, which overheats the testicles.” Turek went on to reassure readers that the effect was believed to be temporary. “Any infection, particularly an infection that involves fever, can affect sperm production and can affect ovulation,” said Dr. Marcelle Cedars, a reproductive endocrinologist and director of the University of California, San Francisco Center for Reproductive Health. She told NBC News that there is no evidence that COVID-19 would be different from that. While a study of 230 women of childbearing age infected with COVID-19 did not identify significant variations compared to the control group, Northwestern University Endocrinologist and Associate Professor Dr. Eve Feinberg said, “When I think about fertility, I think about what is the likelihood that a couple will take home a healthy baby. There is no question in my mind, or any scientist’s mind, that the highest likelihood of having a healthy baby during this pandemic is by getting vaccinated.”

FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) --PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Company’s proprietary Versamune® T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership. This collaboration seeks to raise awareness of new and developing treatment options, including available clinical trials, for patients with HPV-attributed head and neck cancer diagnoses. Unlike many other cancers, the incidence of head and neck cancer is increasing in the United States, primarily due to rates of infection with human papillomavirus (HPV). Because head and neck cancer is often diagnosed at later stages, treatment is often more difficult and more invasive. PDS Biotech is working to change the landscape of HPV-attributed head and neck cancer treatment with their lead candidate, PDS0101, which uses Versamune® to activate the immune system to recognize HPV-associated cancer cells and respond by inducing T-cells to attack and destroy them. Partnerships such as the one between PDS Biotech and HNCA are becoming more common in the patient advocacy and biotechnology spaces. By combining their efforts, partners can more efficiently spread the word about emerging treatments, clinical trials, and additional options for patients who may not have responded to traditional therapies. “Raising awareness of treatment options for patients and their families who are dealing with head and neck cancer that has returned or spread is critical,” said Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. “Treatment options for these patients can be limited and the search often expands to include investigational therapies being studied in clinical research. We’re excited to partner with the HNCA to raise awareness of these options for patients and physicians.” “There are exciting things happening in clinical research for head and neck cancer therapies,” said Amanda Hollinger, Executive Director of HNCA. “Partnering with companies like PDS Biotech who are leading the way forward and working together to raise awareness of new and developing treatment options brings hope to patients, survivors, and families of those battling cancer, as well as offering new avenues of treatment for clinicians.” Head and neck cancer refers to cancers that arise in the mouth, voice box, throat, sinuses, nasal cavity, or salivary glands. Worldwide in 2021, there will be more than 650,000 new cases of oral, head and neck cancer diagnosed and approximately 330,000 deaths from these cancers. Over the last few decades, there has been a 225% increase in HPV-attributed head and neck cancer diagnoses. In 2018, head and neck cancer surpassed cervical cancer as the most common HPV-attributed cancer in the United States. About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The company’s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers. To learn more, please visit or follow us on Twitter at @PDSBiotech. About PDS0101 PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune® platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively. About Head and Neck Cancer Alliance HNCA’s mission is to advance prevention, detection, treatment and rehabilitation of oral, head and neck cancer through public awareness, research, advocacy and survivorship. As the one-stop center for patients, survivors, and family members seeking information about head and neck cancer, HNCA provides support to head and neck cancer patients throughout the year and works in partnership with healthcare, corporate, and community partners to raise awareness of ongoing research in head and neck oncology and educate the public in the disease process, treatment and prevention of oral, head and neck cancers. Led by a Board of Directors with expertise in head and neck surgery, research, and survivorship, HNCA develops strategic priorities to tackle the challenges facing those impacted by this disease. Forward Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. PDS Biotech Media & Investor Relations Contact: Deanne Randolph PDS Biotech Phone: +1 (908) 517-3613 Email: drandolph@pdsbiotech.com Rich Cockrell CG Capital Phone: +1 (404) 736-3838 Email: rich@cg.capital

Infections in Pregnant Women Drive Demand for Effective Women’s Health Diagnostics Solutions High risks associated with the transmission of infectious diseases to pregnant women have raised concerns about effective diagnosis of various infections. As such, infectious disease testing type segment of the women’s health diagnostics market is projected to reach a value of ~US$ 19.2 Bn by the end of 2027. Hence, leading players in the market for women’s health diagnostics are increasing their efficacy in laboratory testing solutions to improve patient outcomes. For instance, leading global medical technology company Siemens Healthineers, offers a range of laboratory testing solutions for women related to TORCH (toxoplasmosis, other (e.g., syphilis, HIV), rubella, cytomegalovirus (CMV), and herpes simplex virus) infections, malnutrition, and bone diseases. Request Brochure of Report - Healthcare companies in the women’s health diagnostics market are tapping into opportunities in diagnostic laboratory testing and infectious disease testing, as both the segments are anticipated to grow rapidly during the forecast period. Growing prevalence of infections causing miscarriage and birth defects in infants are fueling the demand for efficacious treatment options in women’s health diagnostics. Request for Analysis of COVID-19 Impact on Women’s Health Diagnostics Market – Strategic Mergers Offer New Reproductive Health Solutions for Asian Women Apart from expanding product portfolios, companies in the market for women’s health diagnostics are strengthening their global presence through inorganic strategies such as mergers and acquisitions. For instance, in August 2019, Nova Satra Dx - a provider of innovative diagnostics for cancer, announced its merger with a Singapore-based molecular diagnostic company INEX Innovations Exchange Pte. Ltd., to offer healthcare solutions tailored for Asian women. As such, Asia Pacific accounts for the third-highest revenue in the women’s health diagnostics market. This market in Asia Pacific is anticipated for exponential growth during the forecast period. Companies are collaborating to offer enhanced treatment options in Asia Pacific. Efforts are being made to increase the availability of faster and more accurate diagnostic tests to improve quality of life in patients. The concept of precision healthcare is another key driver that is creating incremental opportunities for companies. The women’s health diagnostics market is undergoing change with increased efforts toward providing women’s reproductive health solutions. Buy Women’s Health Diagnostics Market Report at New Testing Approaches Create Revenue Opportunities for Companies and Healthcare Providers Complications associated with cervical cancer has led to the availability of new tests for early detection of the human papillomavirus (HPV). As such, in terms of test type, the cervical cancer testing segment of the women’s health diagnostics market is estimated to reach a value of ~US$ 12.5 Bn by 2027. Hence, companies are introducing new testing options to determine the type of HPV that may lead to cancer. Top of Form Ask for Discount : Companies in the women’s health diagnostics market are increasing R&D to study the ‘two-for-one’ diagnostic approach that not only detects the type of HPV infection, but also evaluates precancerous makers. Patients are increasingly benefitting from this approach, since it serves as a low-cost alternative to diagnose the riskiest forms of HPV infection. Thus, to cater to the convenience of patients, companies in the market for women’s health diagnostics are collaborating with research labs to improve outcomes that help to avoid unnecessary diagnostic procedures. Moreover, healthcare providers are increasing efficacy in novel in-vitro molecular diagnostics procedures to assess high-risk HPV infections. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: